Multicellular living organisms and unmodified parts thereof and – Nonhuman animal
Patent
1993-12-29
1997-02-11
Campell, Bruce R.
Multicellular living organisms and unmodified parts thereof and
Nonhuman animal
800DIG1, 424 92, 435 4, 435 6, 435 29, 4351723, 435325, 435352, 435353, 435354, 935 19, 935 59, 935 70, 935 77, 935 84, C12N 500, C12N 1500, A61K 4900
Patent
active
056023006
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
The invention relates to a process for detecting mutations in the DNA of a transgenic mammal or a transgenic mammalian cell, which DNA contains one or more copies of a marker gene located in a bacterial cloning vector, comprising isolating DNA from cells of the transgenic mammal or the transgenic mammalian cells, recovering the vector from the isolated DNA, transforming a suitable bacterial host with the recovered vector and determining mutations that have occurred in the marker gene on the basis of expression of the marker gene in the host.
The invention relates more particularly to a transgenic animal model provided with a marker gene which is integrated in the genome and which, after isolation of chromosomal DNA, can be recovered efficiently. After transfer of the marker gene to a bacteria incapable of host restriction, a selection is made on the presence of a mutated marker gene to determine the mutation frequency.
Such an animal model is of importance inter alia for testing agents for carcinogenic properties. All newly obtained compounds are in principle suspected of carcinogenicity. According to present day insights they could change the structure of heritable material present in every cell core. Such changes of the heritable material (mutations) can result among other things in cancer. Mutagenic agents (agents which cause mutations in the DNA) are as far as is known also carcinogenic and can likewise cause mutations in the germ cells, which can lead to hereditary genetic deviations. The mutagenicity of an agent is considered the most important criterion in determining the risk of developing cancer or hereditary deviations. It is therefore of particular importance to be able to determine the mutagenicity of an agent at an early stage.
The best known process to date for testing potentially mutagenic agents is the Ames test (Ames, 1973) wherein mutations are detected in bacteria. Although this test can be performed quickly because of the short generation times of a bacteria, extensive research has demonstrated that the predictive value of the Ames test is not 100% (Hay, 1988; Ashby and Tennant, 1988). Preference is therefore generally given to a combination of tests including tests with cultured (in vitro) mammalian cells.
There are at this moment only a few possibilities of detecting mutations in vivo in cells of higher animals. An example is the HPRT test, wherein mutations in the hypoxanthine phosphoribosyl transferase (HPRT) gene are detected on the basis of the 6-thioguanine resistance of the mutated cells (Albertini, 1982). This process is however labour-intensive and only allows measurements on cells that can still divide and are simple to culture. In addition, the artificial nature of the in vitro situation is a drawback to this process, whereby it is difficult to draw conclusions concerning induced mutations in organs and tissues and possible differences between them. An alternative hereto is the use of laboratory animals (particularly rodents) in long-term studies. Animals are exposed herein to a suspect agent and there is a wait to see whether or not tumours appear. This is a time-consuming process however which can last several years and requires many animals, particularly when low concentrations of a suspect agent are being tested. This makes the test very expensive, whereby agents which are positive in the Ames test are often not tested further and do not therefore become commercially available.
A good alternative is the use of transgenic animals as described by Vijg and Uitterlinden (1987), Lohman et al. (1987) and Gossen et al. (1989) and in the European patent application EP-A-0 353 812. The transgenic mouse model described therein contains in each body cell, including the germ cells, a bacteriophage lambda vector in which the bacterial lacZ gene is cloned which serves as the mutation target gene. The vector can be recovered in efficient manner from chromosomal DNA by means of in vitro packaging of the vector in "empty" phage particles. The vector-containin
REFERENCES:
patent: 5128256 (1992-07-01), Huse et al.
patent: 5347075 (1994-09-01), Sorge
Gerhardt et al (1981) Manual of Methods for General Bacteriology pp. 229-234.
Reik (1993) In:Transgenic Animals, F Grosveld et al, eds, p. 103.
RM Strojek et al (1988) In Genetic Engineering: Principles and Methods v. 10, pp. 221-246.
M Dreyfus et al (1985) J Mol. Biol. 182:411-417.
J Lundeberg et al (1990) Genet Anal Techn Appl 7:47-52.
M Uhlen (1989) Nature 340:733-734.
"Germ-Line Transformation Of Mice," Ann. Rev. Genet., vol. 20, pp. 465-499 (1986).
Gossen Jan A.
Vijg Jan
Campell Bruce R.
Ingeny B.V.
LandOfFree
Process for detecting mutations, transgenic mammal transgenic ma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for detecting mutations, transgenic mammal transgenic ma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for detecting mutations, transgenic mammal transgenic ma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-343586